Primus In News
Sudeep Pharma IPO gets fully subscribed on Day 1, GMP signals strong listing: Should you apply?
24-11-2025
Shravan Shetty, Managing Director, Primus Partners, shared his view that Sudeep Pharma is commanding a premium due to steady revenue growth over the last three years and strong mid-20s EBITDA margins, which are higher than many peers in the specialty pharma-ingredients space. He also highlights that with a customer base across 70 countries and exports forming a significant share of revenues, the company benefits from strong product and geographic diversification.
Explore Related Insights
- Indian banks need to quell a looming threat as savers flock to stocks
- Auto industry’s ability to hike prices will be lower in FY25 but value growth to be strong: Primus Partners
- LIVE BLOG Budget 2024 Highlights Updates: Nirmala Sitharaman lists 9 developmental priorities in 83-minute Budget speech
- Education Budget 2023: Edtech sector welcomes new nursing colleges, teacher training initiatives
